{"id":3016,"date":"2023-08-31T18:52:43","date_gmt":"2023-08-31T18:52:43","guid":{"rendered":"https:\/\/cm.vastapps.dev\/tcia-collection\/her2-tumor-rois\/"},"modified":"2023-09-13T11:59:30","modified_gmt":"2023-09-13T11:59:30","slug":"her2-tumor-rois","status":"publish","type":"tcia_collection","link":"https:\/\/cm.vastapps.dev\/tcia-collection\/her2-tumor-rois\/","title":{"rendered":"HER2-TUMOR-ROIS"},"featured_media":7884,"template":"","citation-tax":[],"cancer_types":["HER2+ Breast Cancer"],"citations":[2946,2947,2925],"collection_doi":"10.7937\/E65C-AM96","collection_download_info":"Click the Versions tab for more info about data releases.","collection_downloads":[3148,3149],"full_export":"

Summary<\/h1><\/span>The current standard of care for many patients with HER2-positive breast cancer is neoadjuvant chemotherapy in combination with anti-HER2 agents, based on HER2 amplification as detected by in situ hybridization (ISH) or protein immunohistochemistry (IHC). However, hematoxylin & eosin (H&E) tumor stains are more commonly available, and accurate prediction of HER2 status and anti-HER2 treatment response from H&E would reduce costs and increase the speed of treatment selection. Computational algorithms for H&E have been effective in predicting a variety of cancer features and clinical outcomes, including moderate success in predicting HER2 status. We trained a CNN classifier on 188 H&E whole slide images (WSIs) manually annotated for tumor regions of interest (ROIs) by our pathology team. Our classifier achieved an area under the curve (AUC) of 0.90 in cross-validation of slide-level HER2 status and 0.81 on an independent TCGA test set. Moreover, we trained our classifier on pre-treatment samples from 187 HER2+ patients that subsequently received trastuzumab therapy. Our classifier achieved an AUC of 0.80 in a five-fold cross validation. Our work provides an H&E-based algorithm that can predict HER2 status and trastuzumab response in breast cancer at an accuracy that may benefit clinical evaluations. Here, we are providing the datasets used in the study to facilitate development of other HER2+ diagnosis and trastuzumab response applications.<\/span>

Data annotation<\/strong><\/h3>

Annotation of digital slides was performed, circling areas of invasive carcinoma (Region of Interests, ROIs). The manual annotation of ROIs significantly enhances the prediction accuracy and reduces the need for extensively large datasets.\u00a0 <\/span>Regions of necrosis, in situ carcinoma or benign stroma and epithelium were excluded. The images were annotated with ROIs associated to HER2+\/- tumor area (TA) by a senior breast pathologist.\u00a0 The annotations were marked tumor boundaries and annotated by Aperio ImageScope software. The annotations were exported from the Aperio software in The Extensible Markup Language (XML) format, including X and Y coordinates corresponding to the annotated regions. We used these coordinates for each slide image to tile these regions separately from the rest of the image, labeled as HER2+ or HER2- class.\u00a0\u00a0<\/p>

Description of data sets<\/strong><\/h3>

Yale HER2 cohort:<\/strong>\u00a0This dataset presents 192 cases of HER2 positive and negative invasive breast carcinomas H&E slides from the Yale Pathology electronic database. All tissues and data were retrieved under permission from the Yale Human Investigation Committee protocol #9505008219 to DLR. HER2 positive cases defined as those with 3+ score by immunohistochemistry (IHC) or an equivocal (2+) IHC score with subsequent amplification by fluorescence in situ hybridization (FISH) as defined by American Society of Clinical Oncology\/College of American Pathologists (ASCO\/CAP) clinical practice guidelines. H&E slides generated at Yale School of Medicine include 93 HER2+ and 99 HER2- slides. The slides were scanned at Yale Pathology Tissue Services and underwent a slide quality check before they went into the scanner. The tissue samples were scanned using Vectra Polaris by Perkin-Elmer scanner using bright field whole slides scanning at 20\u00d7 magnification at Brady Memorial Laboratory Rimm\u2019s lab.<\/p>

Yale trastuzumab response cohort:<\/strong> 85<\/span>\u00a0response cohort cases were identified also by retrospective search of the Yale Pathology electronic database. Cases included those patients with a pre-treatment breast core biopsy with HER2 positive invasive breast carcinoma who then received neoadjuvant targeted therapy with trastuzumab +\/- pertuzumab prior to definitive surgery. HER2 positivity was defined as previously described for the HER2 negative\/positive cohort. The response to targeted therapy was obtained from the pathology reports of the surgical resection specimens and dichotomized into responders or non-responders. Those with a complete pathologic response, defined as no residual invasive, lymphovascular invasion or metastatic carcinoma, were designated as responders (n=36). Cases with only residual in situ carcinoma were included in the responder category. Those cases with any amount of residual invasive carcinoma, lymphovascular invasion or metastatic carcinoma were categorized as non-responders (n=49).<\/p>

TCGA HER2 cohort:<\/strong>\u00a0A total of 668 TCGA-BRCA HER2+\/- samples with available HER2 status were downloaded from the GDC portal (see "Additional Resources<\/strong>" below). Slides were visually inspected by our pathology team to exclude low quality samples with tissue folding or those that appeared to be from frozen tissue. A total of 182 samples (90 HER2- and 92 HER2+) were retained for use as independent test set.\u00a0 Information about which specific samples were retained can be found the\u00a0TCGA_BRCA_Filtered<\/span><\/a>\u00a0folder of the dataset.<\/p>

<\/p>